Last updated on June 2020

Study to Test the Safety and How Radium-223 Dichloride an Alpha Particle-emitting Radioactive Agent Works in Combination With Pembrolizumab an Immune Checkpoint Inhibitor in Patients With Stage IV Non-small Cell Lung Cancer With Bone Metastases

Brief description of study

The purpose of the study is to determine the safety and test the efficacy of the combination of radium-223 dichloride and pembrolizumab in patients with stage IV non-small cell lung cancer (NSCLC) with bone metastases who either have not received any systemic therapy for their advanced disease or have progressed on prior immunologic checkpoint blockade with antibodies against the programmed cell death protein-(ligand) 1 (PD-1/PD-L1). In this study researchers want to measure tumor shrinkage in response to treatment and how long that shrinkage lasts and gather information on safety. Pembrolizumab is an immunologic checkpoint blocker that promotes an immune response against the tumor. Radium-223 dichloride is an alpha particle-emitting radioactive agent which kills cancer cells.

Clinical Study Identifier: NCT03996473

Find a site near you

Start Over

Highlands Oncology Group, PA

Fayetteville, AR United States
  Connect »

Levine Cancer Institute

Charlotte, NC United States
  Connect »

CTCA Southwestern

Tulsa, OK United States
  Connect »

UPMC Shadyside

Pittsburgh, PA United States
  Connect »

Carilion Clinic

Roanoke, VA United States
  Connect »

UZ Brussel

Bruxelles - Brussel, Belgium
  Connect »

UZ Gent

Gent, Belgium
  Connect »

Freeman Hospital

Newcastle Upon Tyne, United Kingdom
  Connect »

Recruitment Status: Open

Brief Description Eligibility Contact Research Team

Volunteer Sign-up

Sign up for our FREE service to receive email notifications when clinical trials are posted in the medical category of interest to you.